Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01448915 · ClinicalTrials.gov registry record
Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 828
- Enrollment target
NCT01448915: Completed study, sponsored by Johns Hopkins University.
NCT01448915 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 828 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01448915 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 828 participants
- Enrollment target
Study Summary
The principal goal of this research project is to evaluate the natural history of HCV and liver disease and its treatment in HIV-infected persons who use drugs. Research procedures will focus on determining liver disease prevalence and severity within this population. This is an observational study without study specific interventions.
Primary Outcome
The proportion of persons with HIV and HCV coinfection who achieve HCV cure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 828 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2021-03-31 |
What the finished NCT01448915 record still lists
NCT01448915 is an observational study that tracks outcomes without assigning an intervention. The registered 828 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01448915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01448915 about?
NCT01448915 is a clinical study titled "Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)". The principal goal of this research project is to evaluate the natural history of HCV and liver disease and its treatment in HIV-infected persons who use drugs. Research procedures will focus on determining liver disease prevalence and severity within this population. This is an observational study ...
What is the current status of trial NCT01448915?
This trial is currently completed. The enrollment target is 828 participants. The study started on 2021-03-31. Estimated completion is 2021-03-31.
Who is sponsoring clinical trial NCT01448915?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124808 · 828 participants · NA
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- NCT03547973 · 827 participants · Phase 2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI